Radiation for Hodgkin's Disease Raises Threat of Breast Cancer in Young Women

Young women with Hodgkin's disease who receive radiation therapy, often the standard treatment, are at increased risk for breast cancer, according to a study supported by the National Cancer Institute (NCI).

To determine the risk of breast cancer, NCI grantees Drs. Steven L. Hancock and Richard T. Hoppe of the Stanford University Medical Center in California, and Dr. Margaret A. Tucker of NCI, reviewed the medical records of nearly 900 patients who were treated for Hodgkins' disease during a three-decade span (1961-1990).

The investigators found that age at irradiation and length of time following therapy proved extremely critical in determining breast cancer risk. The risk increased if patients were younger than age 30 when treatment first began, and increased even more if 15 or more years had passed since radiation therapy was administered in the young women.

As a group, Hodgkin's patients of all ages who received any type of treatment were at a fourfold increased risk for breast cancer, compared with general population rates. Hodgkin's patients treated with radiation at ages 24-29 were at seven times the risk; if younger than 15 when receiving radiotherapy, the risk for breast cancer increased by 136 times.

The findings highlight the significance of vigilant, long-term monitoring of young female patients treated for Hodgkin's disease, which strikes 7,900 Americans each year, including 3,400 females.

Source

Hancock, S.L., M.D., et al., "Breast Cancer After Treatment of Hodgkin's Disease," Journal of the National Cancer Institute, pp. 25-31, Jan. 6, 1993.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap